Doris Benbrook to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Doris Benbrook has written about Drug Screening Assays, Antitumor.
Connection Strength
0.432
-
Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42.
Score: 0.082
-
High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov; 58(5):561-9.
Score: 0.064
-
Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007.
Score: 0.055
-
Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J Med Chem. 2001 Jul 05; 44(14):2308-18.
Score: 0.046
-
Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25.
Score: 0.045
-
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
Score: 0.044
-
Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem. 1999 Oct 21; 42(21):4434-45.
Score: 0.041
-
Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17.
Score: 0.030
-
Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011 Dec 15; 312(1):11-7.
Score: 0.023